Fidelity National Information Services (FIS)

Private credit remains a "compelling asset class," despite recent headlines, Fidelity Investments said in a recent report.

Capital flows are telling a certain story, but it might deceive you.

The Vanguard Dividend Appreciation ETF (VIG) focuses on companies with a long record of raising dividends, while the Fidelity High Dividend ETF (FDVV) leans toward stocks offering higher current dividend payouts. This comparison looks at how those approaches influence not just income levels today, but how that income can hold up as market conditions change.

As of March 17, 2026, the long-promised "quantum era" has moved from the realm of science fiction into the corridors of corporate strategy. International Business Machines (NYSE: IBM) has unveiled a series of architectural breakthroughs that are fundamentally reshaping the competitive landscape of high-performance computing. By successfully deploying its Quantum

IonQ and SoundHound are two speculative stocks with a lot of upside.

As of March 17, 2026, Lululemon Athletica Inc. (NASDAQ: LULU) stands at one of the most significant crossroads in its 28-year history. Once the undisputed titan of the premium athleisure market, the Vancouver-born company is currently navigating a complex "valuation reset" that has seen its stock price fall from historical highs of over $500 in [...]

Explore how differences in cost, risk, and portfolio breadth could impact your choice between these two bond ETFs.

Bitcoin’s daily transactions stayed steady in recent months, ranging between about 350,000 and 450,000 per day, Blockworks data shows.

Everyone's got their own number, but there is a right (minimum) number for everyone.

Fidelity examined what price per barrel of oil would need to reach for consumers to cut back hard enough to drag down the broader economy.

The new Sqale quantum platform will enable scientists to experiment with large quantum systems to address problems in materials science and energy, among others.

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...

Explore how sector tilts, yield focus, and portfolio strategy set these dividend ETFs apart for income-minded investors.

IonQ and D-Wave Quantum are two of the top investment options in the industry.

Broadridge Financial Solutions has underperformed its sector peers recently, yet analysts remain moderately optimistic about the stock’s prospects.

The Schwab U.S. Dividend Equity ETF (SCHD) emphasizes durable dividend payers with strong financial health, while the Fidelity High Dividend ETF (FDVV) mixes dividend income with exposure to large growth companies. Understanding how these strategies differ can help investors decide whether their dividend allocation should prioritize income stability or participation in market-leading stocks.

Today’s Date: March 13, 2026 Introduction As of March 2026, the global technology landscape has undergone a paradigm shift, transitioning from the experimental phase of Generative AI to a period of industrial-scale deployment. Standing at the epicenter of this transformation is Broadcom Inc. (NASDAQ: AVGO), a company that has evolved from a diversified chipmaker into [...]

The quantum computing powerhouse has already lost over 60% of its peak value, but more downside could be on the way.

Identical yields mask key differences in sector exposure and risk, making portfolio fit a crucial factor for income-focused investors.

Expense ratios, sector tilts, and portfolio concentration set these two dividend ETFs apart for income-focused investors.

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]

Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) released long-awaited Phase 3 results for its lead candidate, azetukalner (formerly XEN1101), sending its stock price soaring by 46.5%. The X-TOLE2 trial, which evaluated [...]